Hyperfine Reports 128% Revenue Surge in Q4 2025, Eyes 55% Growth in 2026

Event summary

  • Hyperfine reported Q4 2025 revenue of $5.29M, up 128% YoY, with full-year 2025 revenue at $13.56M (+5.2% YoY).
  • Sold 16 Swoop® systems in Q4 2025, up from 9 in Q4 2024, with 38 systems sold in 2025 vs. 48 in 2024.
  • Gross margin improved to 51% in Q4 2025 from 36% in Q4 2024, with full-year 2025 gross margin at 50% vs. 46% in 2024.
  • Raised $20M in equity offering in October 2025 and secured a $40M term loan facility in March 2026.
  • Expects 2026 revenue of $20–$22M (55% growth) and cash burn of $26–$28M (10% decline).

The big picture

Hyperfine’s strong Q4 2025 performance reflects growing demand for its portable MRI technology, particularly in neurology offices. The company’s strategic focus on AI-powered imaging and regulatory advancements positions it to capitalize on the shift toward decentralized diagnostic care. However, its ability to maintain momentum amid competitive pressures and high R&D costs will be crucial.

What we're watching

Commercial Expansion
The pace at which Hyperfine can scale its Swoop® system adoption across hospitals, neurology offices, and international markets will determine its revenue trajectory.
Regulatory Milestones
Progress in the Contrast PMR study and other clinical trials will be critical for expanding the Swoop® system’s intended use and market potential.
Financial Discipline
Whether Hyperfine can sustain its improved gross margins and manage cash burn effectively will be key to its long-term viability.